{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allogeneic+Stem-Cell+Transplant&page=17",
    "query": {
      "condition": "Allogeneic Stem-Cell Transplant",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1030,
    "total_pages": 103,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allogeneic+Stem-Cell+Transplant&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allogeneic+Stem-Cell+Transplant&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T06:42:29.067Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00006968",
      "title": "Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "pentostatin",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2000-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-08",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006968"
    },
    {
      "nct_id": "NCT00566696",
      "title": "Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Acute Lymphocytic (ALL)",
        "Leukemia, Myeloid, Acute(AML)",
        "Leukemia, Myeloid, Chronic(CML)",
        "Juvenile Myelomonocytic Leukemia (JMML)",
        "Hemoglobinuria, Paroxysmal Nocturnal (PNH)",
        "Hodgkin Lymphoma",
        "Lymphoma, Non-Hodgkin (NHL)",
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "CliniMACS",
          "type": "DEVICE"
        },
        {
          "name": "Stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Thioplex®",
          "type": "DRUG"
        },
        {
          "name": "L-phenylalanine mustard",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Rituxan™",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Anti-thymocyte globulin (Rabbit)",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Muromonab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 73,
      "start_date": "2007-12-14",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2020-04-14",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00566696"
    },
    {
      "nct_id": "NCT00548717",
      "title": "Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft-vs-Host Disease"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2007-10",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2014-10-21",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00548717"
    },
    {
      "nct_id": "NCT06453460",
      "title": "CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CMV",
        "Allogeneic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Letermovir",
          "type": "DRUG"
        },
        {
          "name": "CMV T Cell Immunity Panel (CMV-TCIP)",
          "type": "DEVICE"
        },
        {
          "name": "CMV DNA PCR",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-06-27",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06453460"
    },
    {
      "nct_id": "NCT03939585",
      "title": "Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allogeneic Stem Cell Transplant Candidate",
        "Acute Myeloid/Lymphoblastic Leukemia",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Lymphoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "Cellular therapy product",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Leland Metheny",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-12-01",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03939585"
    },
    {
      "nct_id": "NCT00511550",
      "title": "Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 15,
      "start_date": "2005-08",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2008-03-05",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511550"
    },
    {
      "nct_id": "NCT00423774",
      "title": "Education Program to Manage Emotional Stress of Stem Cell Transplant Recipients and Their Caregivers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Family Caregivers",
        "Bone Marrow Transplantation"
      ],
      "interventions": [
        {
          "name": "Problem-Solving Education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-01-11",
      "completion_date": "2008-12-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423774"
    },
    {
      "nct_id": "NCT02086513",
      "title": "Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "LDE225",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2014-04",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2018-03-19",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02086513"
    },
    {
      "nct_id": "NCT02133924",
      "title": "Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "natalizumab",
          "type": "DRUG"
        },
        {
          "name": "steroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Levine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2016-08",
      "completion_date": "2021-11-21",
      "has_results": true,
      "last_update_posted_date": "2022-10-21",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02133924"
    },
    {
      "nct_id": "NCT00048737",
      "title": "Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Zevalin Radioimmunotherapy",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Stem Cell Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 70,
      "start_date": "2002-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-06-13",
      "last_synced_at": "2026-10-15T06:42:29.067Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048737"
    }
  ]
}